GSK reports promising early results in ovarian and womb cancer drug trial

GSK's early-stage trial of Mocertatug Rezetecan, known as Mo-Rez, showed tumour reduction or elimination in 62% of ovarian and 67% of endometrial cancer patients. This promising treatment has prompted GSK to initiate late-stage trials globally, with peak sales projected at over £2 billion. GSK aims to bolster its oncology portfolio after reviving its cancer research efforts.

Summary by Glance · The Guardian Australia – Business